Study of Tislelizumab With Chemotherapy or Radiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Esophageal squamous cell carcinoma (ESCC), one of the most common subtypes of esophageal
cancer, has a poor prognosis and low 5-year overall survival. At present, the treatment of
ESCC includes chemotherapy, immunity, radiotherapy, surgery and other methods, and in recent
years, the treatment regimen of immune combined chemotherapy has begun to show results in the
treatment of esophageal cancer. Tislelizumab has demonstrated good efficacy in advanced
esophageal cancer and in the second- and third-line treatment. At present, neoadjuvant
immunization is carried out less, and neoadjuvant immunization plus chemoradiotherapy has
been achieved With a pCR rate of 55.6 and AEs of grade III and above 65%, and studies have
shown that radiotherapy has immunosensitizing and coordinating effects, whether immunotherapy
combined with radiotherapy has a better efficacy is worth further investigation. This review
intends to conduct a randomized, open-label, uncontrolled study of tislelizumab in
combination with chemotherapy or radiation therapy for neoadjuvant therapy for resectable
locally advanced thoracic esophageal squamous cell carcinoma with a view to providing a new
option for resectable locally advanced ESCC.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University